SPRO is Spero Therapeutics, Inc. (Healthcare) — a non-dividend-paying stock. Trading at $1.21. Market cap: $71M. Capital Quality Rank: 39/100 — Stagnant mediocrity.
Stock snapshot
| Price | $1.21 |
| Market cap | $71M |
| Sector | Healthcare |
| Exchange | NMS |
| Pays dividend | No |
Capital Quality & fundamentals
DiviDrip's Capital Analytics engine ranks every non-dividend stock 1-100 on a 4-factor composite (Shareholder Yield 30%, Cash-Flow ROI 25%, Operating Momentum 25%, Tail-Risk 20%) — sector-neutralized so a biotech isn't penalized for negative earnings the way a utility would be.
| Capital Quality Rank (1-100) | 39 / 100 · Stagnant mediocrity |
| ROIC (TTM) | 26.5% |
| Revenue CAGR (3y) | 7.7% |
| Shareholder buyback yield | -8.47% |
| Altman Z-score zone | Distress |
About SPRO
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Related non-dividend companies
Other non-dividend stocks investors research alongside SPRO. Peer set from Massive news + returns similarity, filtered to names we currently track.
Frequently asked
What is SPRO's current stock price?
SPRO (Spero Therapeutics, Inc.) is currently trading at $1.21.
Does SPRO pay a dividend?
SPRO (Spero Therapeutics, Inc.) does not currently pay a regular dividend.
What is SPRO's Capital Quality Rank?
SPRO has a Capital Quality Rank of 39/100 — Stagnant mediocrity. This score blends ROIC, revenue growth, buybacks, and balance-sheet health.
Track SPRO in DiviDrip
Add SPRO to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search SPRO and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-05. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.